Thomas R. Cox, Oct 2019
Working together with A/Prof Paul Timpson’s lab, we are pleased to announce that our recent review on targetting CAFs in pancreatic cancer has just been published in Trends In Cancer.
In this work we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC).
Thomas R. Cox, Aug 2019
We are super excited to announce that our recent work in close collaboration with A/Prof Paul Timpson has just been published in Nature Communications (view the full Open-Access article here)
In this work (which was a large international collaboration), co-led by our team and Paul Timpson’s team (also at the Garvan Institute), we show that remodeling of the stromal tissue in and around pancreatic tumours may be the key to stopping their spread and improving chemotherapy outcomes.
We already know that tumours are made up of heterogenous populations of cancer cells with different mutational landscapes. Furthermore, recently, the field has begun to realise that the cancer associated fibroblasts (CAFs) present in and around the tumour are also a diverse collection of subpopulations.
Thomas R. Cox, Aug 2019
It’s with great excitement that we welcome our newest PostDoc to the team, Amelia Parker.
Amelia joins us having returned from a PostDoctoral position at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the USA. Prior to this she completed her Ph.D. in the laboratories of Professor Maria Kavallaris and A/Prof Joshua McCarroll at The Children’s Cancer Institute (CCI) in Sydney.
As a biomedical engineer and cancer biologist, Amelia is interested in the importance of the tumour microenvironment, and in particular the extracellular matrix (ECM) in driving tumour progression.
Amelia’s work will focus on the importance of the ECM in Lung Cancer onset and progression.
Thomas R. Cox, Aug 2019
Just published in Cancer Reports is our new protocol paper detailing the development of a rapid high-throughput (96wp) 3D organotypic coculture assay that is optimised for screening cancer cell and cancer-associated fibroblast response to drugs in physiologically relevant matrices.
Thomas R. Cox, May 2019
Our lab has contributed to a recent paper by Zeltz and colleagues looking at the interplay between Lysyl Oxidase Like 1 (LOXL1) and Integrin α11 in Non-Small Cell Lung Cancer (NSCLC). The work was published in the Open-Access journal Cancers.
Thomas R. Cox, May 2019
A new paper has just been published revealing the role of Lysyl Oxidase Like 2 (LOXL2) in the remodelling of the prostate cancer microenvironment. The work, carried out in collaboration with lead researchers from the Cancer Program, Biomedicine Discovery Institute at Monash University has just been published in Molecular and Cellular Proteomics.
Thomas R. Cox, Mar 2019
Great news! The Matrix & Metastasis Lab been awarded a three-year project grant from Cancer Council NSW to explore a new combination approach to treating pancreatic cancer.
The project will look at how to target the Lysyl Oxidase (LOX) family of enzymes in in pancreatic cancer with the goal of improving outcomes in patients.
Pancreatic cancer has one of the poorest survival rates of all cancer, with only 25% of people surviving one year after diagnosis and only 8% for five years. This project will look at the tissue in and around pancreatic cancers, which can affect how successful chemotherapy treatment is in a patient.
The aim is to combining biology and engineering to generate 3D models that mimic tumours, along with cutting edge imaging technology and mouse models, to investigate the potential of co-targeting the Lysyl Oxidase family together with already approved cancer drugs to improve patient outcome.
Dr Thomas Cox receiving the award on behalf of the team at CCNSW’s annual Research Awards Evening.
Thomas R. Cox, Mar 2019
We have just published a new paper in Breast Cancer Research in collaboration with lead researcher Dr. David Croucher from the Garvan Institute, looking at how and why ERBB2 (HER2) positive breast cancer cells develop resistance to targeted therapies such as trastuzumab (Herceptin™).
Thomas R. Cox, Jan 2019
We are looking forward to the imminent arrival of our newest member, Gretel Major who is joining the group this week.
Gretel is joining us a new Research Assistant (RA) in the Matrix and Metastasis team having recently completed her Bachelor of Advanced Science (Honours) degree at the University of Wollongong under the mentorship of Prof. Marie Ranson.
Gretel joins us to work on our different projects underway looking at the role of the extracellular matrix (ECM) in cancer progression, and is particularly interested in developing her translational research skills.
Thomas R. Cox, Jan 2019
Our latest review in collaboration with Dr. David Croucher and Dr. Dirk Fey on ‘The extracellular matrix as a key regulator of intracellular signalling networks‘ has just been published as part of a special series on ‘Translating the Matrix’ in the British Journal of Pharmacology.
Computational model of the interplay between the ECM and drug activated MAPK‐JNK signalling network.
At their simplest, cells follow a set of rules governed by their genetic code. These rules, which are executed by the protein‐based signalling networks that the genes encode, control the assimilation of information and decision‐making processes that shape a cell’s response to their surroundings.
